JP2019163319A5 - - Google Patents

Download PDF

Info

Publication number
JP2019163319A5
JP2019163319A5 JP2019104081A JP2019104081A JP2019163319A5 JP 2019163319 A5 JP2019163319 A5 JP 2019163319A5 JP 2019104081 A JP2019104081 A JP 2019104081A JP 2019104081 A JP2019104081 A JP 2019104081A JP 2019163319 A5 JP2019163319 A5 JP 2019163319A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
region
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019104081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019163319A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019163319A publication Critical patent/JP2019163319A/ja
Publication of JP2019163319A5 publication Critical patent/JP2019163319A5/ja
Priority to JP2021081392A priority Critical patent/JP7162695B2/ja
Pending legal-status Critical Current

Links

JP2019104081A 2013-11-21 2019-06-04 抗体−薬物コンジュゲート凍結乾燥製剤 Pending JP2019163319A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021081392A JP7162695B2 (ja) 2013-11-21 2021-05-13 抗体-薬物コンジュゲート凍結乾燥製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907001P 2013-11-21 2013-11-21
US61/907,001 2013-11-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016533019A Division JP6590803B2 (ja) 2013-11-21 2014-11-21 抗体−薬物コンジュゲート凍結乾燥製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021081392A Division JP7162695B2 (ja) 2013-11-21 2021-05-13 抗体-薬物コンジュゲート凍結乾燥製剤

Publications (2)

Publication Number Publication Date
JP2019163319A JP2019163319A (ja) 2019-09-26
JP2019163319A5 true JP2019163319A5 (ru) 2020-03-19

Family

ID=51947368

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016533019A Active JP6590803B2 (ja) 2013-11-21 2014-11-21 抗体−薬物コンジュゲート凍結乾燥製剤
JP2019104081A Pending JP2019163319A (ja) 2013-11-21 2019-06-04 抗体−薬物コンジュゲート凍結乾燥製剤
JP2021081392A Active JP7162695B2 (ja) 2013-11-21 2021-05-13 抗体-薬物コンジュゲート凍結乾燥製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016533019A Active JP6590803B2 (ja) 2013-11-21 2014-11-21 抗体−薬物コンジュゲート凍結乾燥製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021081392A Active JP7162695B2 (ja) 2013-11-21 2021-05-13 抗体-薬物コンジュゲート凍結乾燥製剤

Country Status (7)

Country Link
US (3) US10617764B2 (ru)
EP (1) EP3071237A1 (ru)
JP (3) JP6590803B2 (ru)
KR (1) KR102372245B1 (ru)
CN (2) CN113521016A (ru)
MX (1) MX2016006488A (ru)
WO (1) WO2015075201A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011267106B2 (en) * 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor
US10617764B2 (en) * 2013-11-21 2020-04-14 Genmab A/S Lyophilized anti-tissue factor antibody-drug conjugates
EP3319597B1 (en) * 2015-07-10 2021-02-17 Byondis B.V. Compositions comprising antibody-duocarmycin drug conjugates
EP3919081A1 (en) 2015-09-11 2021-12-08 Genmab A/S Dosing regimens for anti-tf-antibody drug-conjugates
WO2017091745A1 (en) 2015-11-25 2017-06-01 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
SG11201805534TA (en) * 2016-01-13 2018-07-30 Genmab As Formulation for antibody and drug conjugate thereof
US11352423B2 (en) * 2016-06-27 2022-06-07 Morphosys Ag Anti-CD19 antibody formulations
CN106938051B (zh) * 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
SG11202006400UA (en) 2018-01-04 2020-08-28 Iconic Therapeutics Inc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
TWI811335B (zh) * 2018-04-13 2023-08-11 美商建南德克公司 穩定抗cd79b免疫結合物調配物
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー/エス 抗pd-1抗体と抗組織因子抗体-薬物コンジュゲートとの組み合わせを用いるがんの治療方法
AU2019266205A1 (en) 2018-05-07 2020-10-22 Genmab A/S Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
AU2019321442A1 (en) * 2018-08-16 2021-02-11 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
TW202034958A (zh) 2018-10-30 2020-10-01 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
KR20220058555A (ko) * 2019-08-15 2022-05-09 실버백 테라퓨틱스, 인크. 벤즈아제핀 접합체의 제형 및 이의 용도
MX2022005222A (es) 2019-11-07 2022-06-08 Genmab As Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
BR112022025105A2 (pt) 2020-06-29 2023-01-17 Genmab As Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco
CN116635077A (zh) * 2020-11-10 2023-08-22 赛诺菲 Ceacam5抗体-药物缀合物制剂
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
EP0417193B1 (en) * 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
WO1994005328A1 (en) * 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Igg 항체의 안정한 액상 약학 제형물
AU2003247686A1 (en) 2002-07-02 2004-01-23 Smithkline Beecham Corporation A novel stable formulation
AU2003242506A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S Tf antagonist
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
TR201808801T4 (tr) 2003-02-10 2018-07-23 Biogen Ma Inc İmmünoglobulin formülasyonu ve bunun hazırlanış yöntemi.
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2006014965A2 (en) 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2007034443A (ja) * 2005-07-22 2007-02-08 Konica Minolta Business Technologies Inc 画像形成システム、画像形成装置及び画像形成処理方法
MX336033B (es) 2005-08-03 2016-01-07 Immunogen Inc Formulaciones de inmunoconjugado.
CN101237881B (zh) * 2005-08-03 2015-04-22 伊缪诺金公司 免疫偶联物剂型
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
KR20090001217A (ko) * 2007-06-29 2009-01-08 삼성전자주식회사 미싱 노즐 검출방법 및 이를 이용하는 잉크젯 프린트 헤드
JP4824710B2 (ja) * 2008-02-08 2011-11-30 国立清華大学 グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5005023B2 (ja) * 2009-12-25 2012-08-22 インターナショナル・ビジネス・マシーンズ・コーポレーション 読出し及び書込み命令の混在するコマンド列を受け取った場合の最適な書込みを実行するリニア記録方式の装置、その方法、及びプログラム。
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
ES2722201T3 (es) * 2010-03-22 2019-08-08 Hoffmann La Roche Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
AU2011267106B2 (en) * 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor
US10617764B2 (en) * 2013-11-21 2020-04-14 Genmab A/S Lyophilized anti-tissue factor antibody-drug conjugates
EP3919081A1 (en) 2015-09-11 2021-12-08 Genmab A/S Dosing regimens for anti-tf-antibody drug-conjugates

Similar Documents

Publication Publication Date Title
JP2019163319A5 (ru)
US10758556B2 (en) Anthracycline-based antibody drug conjugates having high in vivo tolerability
JP6333882B2 (ja) 抗体−薬剤コンジュゲート
KR100812658B1 (ko) 향상된 세포독성 및 수율의 항-이지에프알브이 3,에스씨에프브이에스, 이에 기초한 면역독소, 및 이의 이용방법
ES2788864T3 (es) Conjugados de anticuerpo-fármaco e inmunotoxinas
JP6616776B2 (ja) 抗体−薬物複合体及び免疫毒素
KR20160079890A (ko) 항체-약물 접합체 동결건조 제제
JP2014050409A (ja) 高い結合親和性を有する免疫結合体
JP6585600B2 (ja) C末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法
JP2020509031A5 (ru)
US20200222552A1 (en) Pharmaceutical formulations and methods of use thereof
WO2002043661A3 (en) Recombinant anti-cd30 antibodies and uses thereof
AU2013209512B2 (en) Surrobody cojugates
WO2004064787A3 (en) Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
KR102399028B1 (ko) 이중-특이적 항원-결합 폴리펩티드
RU2020112280A (ru) Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение
IL273384B2 (en) Methods to prevent methionine oxidation in immune conjugates
US20170326252A1 (en) Nanoparticles for Delivery of Agents to Glioblastoma Tumors
US20240091372A1 (en) Anti-doppel antibody drug conjugates
CN113795513A (zh) 抗外周淋巴结地址素抗体及其用途
RU2023123071A (ru) Способы предотвращения окисления метионина в иммуноконъюгатах